Of relevance in ER+/HER2- advanced breast cancer, the therascreen PIK3CA RGQ PCR kit detects PIK3CA mutations to help direct PI3Ka inhibitor treatment (alpelisib)[75,76]. Here, ESR1 is linked to breast carcinoma.